Circulating Monocytes as a Marker of Response to Adalimumab in Patients with Hidradenitis Suppurativa

This retrospective study of 143 patients with hidradenitis suppurativa (HS) treated with adalimumab found that baseline monocyte counts can predict treatment effectiveness. Patients with monocyte counts \(\geq\) 925/\(\mu\)l had a significantly higher risk of adalimumab ineffectiveness, with a hazard ratio of 5.87. Drug survival rates at 12 and 24 months were significantly higher in patients with lower monocyte counts, at 95.7% and 90.6%, compared to 61.5% and 52.7% in those with higher counts. The optimal monocyte count cut-off for predicting response was \(\geq\) 925/\(\mu\)l, with a specificity of 90.5% and sensitivity of 46.2%. Other factors like age, BMI, and HS severity did not significantly affect treatment outcomes.